21
Apr

After keeping investors on a roller coaster ride of speculation for months, Sarepta says it now plans to shoot for an accelerated approval of its Duchenne muscular dystrophy drug eteplirsen. The biotech says it will file for an early approval by the end of this year after launching a slate of new clinical trials to get the data that the FDA is looking for.

…read more

Source: Sarepta rockets up after mapping a shortcut to the FDA with DMD hopeful eteplirsen

    

0 No comments